Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1126/science.adr6933 | DOI Listing |
Am J Psychiatry
January 2025
Department of Psychiatry, NYU Langone Center for Psychedelic Medicine, NYU Grossman School of Medicine, New York (Pagni, Zeifman, Mennenga, Carrithers, Goldway, O'Donnell, Ross, Bogenschutz); School of Life Sciences, Arizona State University, Tempe (Mennenga); Department of Psychology, New York University, New York (Goldway); Department of Psychiatry and Behavioral Sciences, University of New Mexico School of Medicine, Albuquerque (Bhatt).
J Bodyw Mov Ther
October 2024
Department of Graduate Studies in Health and Rehabilitation Sciences, Youngstown State University, 1 Tressel Way, Youngstown, OH, 44555, USA. Electronic address:
Background: Doctor of Physical Therapy (DPT) students report higher levels of stress and anxiety compared to age-matched peers. Increased stress can negatively impact students' physical conditions and academic performance.
Objective: This study aims to incorporate the NIH "Press Reset on Stress" strategies of deep breathing, PMR, and mindfulness into the curriculum for DPT students and evaluate their effectiveness on student-perceived stress, anxiety, and depression.
JAMA Intern Med
November 2024
Mental Health Centre Copenhagen and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Importance: Obesity is associated with numerous psychosocial complications, making psychiatric safety a consideration for treating people with obesity. Few studies have investigated the psychiatric safety of newly available antiobesity medications.
Objective: To evaluate the psychiatric safety of subcutaneous semaglutide, 2.
Lancet Diabetes Endocrinol
September 2024
Department of Medicine, University of Calgary Cumming School of Medicine, Calgary, AB, Canada.
Background: There are currently limited data regarding the effect of semaglutide 2·4 mg in individuals with obesity and prediabetes in clinical trials. We aimed to assess the efficacy and safety of semaglutide 2·4 mg for weight management and glycaemic control in participants with obesity and prediabetes.
Methods: STEP 10 was a randomised, double-blind, parallel-group, phase 3 trial done across 30 trial sites in Canada, Denmark, Finland, Spain, and the UK and included participants aged 18 years or older with a BMI of 30 kg/m or higher and prediabetes according to UK National Institute for Health and Care Excellence criteria (defined as having at least one of the following at screening: HbA of 6·0-6·4% [42-47 mmol/mol] or fasting plasma glucose [FPG] of 5·5-6·9 mmol/L).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!